CD274 and non-small cell lung carcinoma: Anti‐programmed death 1 (anti‐PD‐1), anti‐programmed death ligand 1 (anti‐PD‐L1), anti‐cytotoxic T lymphocyte‐associated antigen 4 (anti‐CTLA‐4), neoadjuvant immune checkpoint inhibitors (NAICIs), and chimeric antigen receptor‐modified T (CAR‐T) are among the current immunotherapy for patients with NSCLC.